Monday, July 28, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Organon Abandons Endometriosis Pain Drug Development After Trial Failure

July 2, 2025
in Health News
Share on FacebookShare on Twitter


(Reuters) -Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with endometriosis.

The drug’s failure in a proof-of-concept mid-stage study deals a blow to the company’s attempt to launch a future driver of revenue, four years after it was spun off from Merck. Another drug acquired by Organon through the up to $954 million Forendo acquisition is still in lab studies.

Organon was testing the drug, OG-6219, in 354 patients aged 18 to 49 who had moderate-to-severe endometriosis-related pain, but results showed no significant improvement compared to a placebo. Improvement in pelvic pain was measured using an 11-point rating scale during the third month of treatment.

Endometriosis is a condition that affects about 190 million women of reproductive age globally, according to the World Health Organization. It occurs when tissue similar to the uterine lining grows outside the uterus, often causing chronic pelvic pain and infertility.

Organon’s study was designed to assess whether the drug could meaningfully reduce pelvic pain and patients were randomly chosen to receive one of three pre-decided doses of the drug or a placebo, given orally twice a day.

Current treatments options for endometriosis include hormonal therapies such as birth control pills, progestins, and GnRH modulators such as Myfembree, co-owned by Sumitovant Biopharma and Pfizer, and AbbVie’s Orilissa.

Pain is often managed with non-steroidal and anti-inflammatory medicines such as ibuprofen and surgery remains an option for severe cases.

OG-6219 is designed to block an enzyme involved in estrogen production, aiming to reduce pain by lowering levels of estradiol at endometriosis sites without affecting hormone levels throughout the body.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)



Source link : https://www.medscape.com/s/viewarticle/organon-abandons-endometriosis-pain-drug-development-after-2025a1000hm9?src=rss

Author :

Publish date : 2025-07-02 12:01:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Glucose Monitoring Shows Dysglycaemia in Premature Infants

Next Post

Teens Oversleeping Post-Concussion May Have Worse Recovery

Related Posts

Health News

Sweeteners and Genetics Linked to Early Puberty Risk

July 28, 2025
Health News

Ovarian Cancer Risk Rises Soon After IBS Diagnosis

July 28, 2025
Health News

Cancer Care Costs High Among Privately Insured Patients

July 28, 2025
Health News

Claims Data Fail to Accurately Identify MI Types

July 28, 2025
Health News

More Data Cement COVID’s Impact on Patients With Cancer

July 28, 2025
Health News

End Non-Medical Vaccine Exemptions, AAP Says

July 28, 2025
Load More

Sweeteners and Genetics Linked to Early Puberty Risk

July 28, 2025

Ovarian Cancer Risk Rises Soon After IBS Diagnosis

July 28, 2025

Cancer Care Costs High Among Privately Insured Patients

July 28, 2025

Claims Data Fail to Accurately Identify MI Types

July 28, 2025

More Data Cement COVID’s Impact on Patients With Cancer

July 28, 2025

End Non-Medical Vaccine Exemptions, AAP Says

July 28, 2025

Nurses union to reject pay deal as strike vote looms

July 28, 2025

‘Make Doctors Great Again’: What We Heard This Week

July 27, 2025
Load More

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version